New insider activity at Artivion ( (AORT) ) has taken place on August 14, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Artivion stock, SVP & GC Jean Holloway sold 23,356 shares, amounting to a total of $1,004,541. Meanwhile, CCO John E Davis sold 10,802 shares, with the sale valued at $471,723.
Recent Updates on AORT stock
In the last 24 hours, Artivion has seen significant developments influencing its stock price. The company reported strong Q2 2025 earnings, with a 14% revenue growth and 33% EBITDA increase, driven by successful product launches like AMDS and On-X, and improved financial stability. These positive results led to several analysts raising their price targets for Artivion. Needham increased its target due to robust On-X and stent graft growth, while Oppenheimer and others cited the company’s strong financial performance and promising pipeline, including NEXUS and Arcevo. Additionally, Artivion appointed Lance A. Berry as COO, further strengthening its leadership team. Despite some challenges like cybersecurity costs and delays in the China BioGlue launch, the overall outlook remains optimistic, with raised guidance reflecting confidence in continued growth.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
Artivion’s overall score is driven by strong earnings call results and positive corporate events, but is weighed down by financial performance challenges and lack of technical analysis data.
To see Spark’s full report on AORT stock, click here.
More about Artivion
YTD Price Performance: 55.73%
Average Trading Volume: 406,007
Technical Sentiment Signal: Buy
Current Market Cap: $2.07B